Talking to your healthcare professional
Here are some questions you may want to ask your healthcare professional. Print out this page and bring the questions to your next appointment. If you have questions of your own, write them in the space provided below. Be sure to write down the answers and any notes so you can refer to them in the future.
- Are there any exercises or diets that could help?
- What is the newest medication for acromegaly?
- Where do I get medicine for acromegaly?
- How do I take medicine for acromegaly?
- Who should receive medical therapy with Somatuline® Depot (lanreotide) Injection?
- How long is the needle?
- How will I know if my treatment is working?
- Will I need to have blood tests?
- What are blood tests for in acromegaly treatment?
- How often will I have to take Somatuline Depot?
- Does Somatuline Depot come premixed?
- What is involved in injecting Somatuline Depot?
- What do you need to know about me before I take Somatuline® Depot (lanreotide) Injection?
- Is Somatuline Depot covered by insurance?
- Is there any way to get help dealing with my pharmacy benefits manager?
Notes:
_______________________________________________
_______________________________________________
_______________________________________________
Indication and Important Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.
A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).
For Full Prescribing Information, click here.
View our